Calliditas
Calliditas [CALTX] is a commercial, biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas is focused on the development and commercialization of its lead product candidate Nefecon, which has successfully completed a Phase 3 clinical trial, as a potential new treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of developing end stage renal disease. Nefecon was approved for the treatment of IgA nephropathy under the accelerated approval pathway by the FDA in December 2021
Sector
Biopharmaceuticals
Strategies
Crossover
Status
Active
Website
www.calliditas.se
Related Articles
Calliditas Announces Positive Topline Results from Pivotal Phase 3 NefIgArd Trial
Calliditas Announces Agreement to Acquire Controlling Interest in Genkyotex SA
Calliditas Therapeutics Prices its Initial Public Offering on The Nasdaq Global Select Market in the United States
Calliditas Appoints New Chief Medical Officer
Calliditas strengthens its US Commercial Organization
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.